CTXR Citius Pharmaceuticals, Inc.
Listings ·
Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million.
Nasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance.
Citius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern.
Nasdaq told Citius Pharmaceuticals on February 9, 2026 that its stock had closed below $1.00 for 30 consecutive business days, and the company has until August 10, 2026 to regain compliance. The same filing reports $3.9 million in first-quarter revenue from LYMPHIR, against $7.7 million in cash.
Citius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price.
The company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31.
Citius Pharmaceuticals sold one share of a newly designated Series A preferred stock for $100 to Chairman and CEO Leonard Mazur on April 17, 2025. The share carries 1,000,000,000 votes on a proposal to raise authorized common shares from 16,000,000 to 250,000,000, and the board also cut the quorum for stockholder meetings to one-third.
Citius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes.
Citius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed.
| Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 |
|---|---|---|
| Research and development | $9.2 million | $11.9 million |
| Cash from operations | -$26.6 million | -$28.2 million |
| Cash and equivalents | $4.3 million | $3.3 million |
Our latest story on this, dated Apr 24, 2026: "Citius Pharmaceuticals prices $5 million registered direct offering at $0.985". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 24, 2026: "Citius Pharmaceuticals prices $5 million registered direct offering at $0.985". The story links the filing or release it is based on. Read the story.
Citius Pharmaceuticals, Inc. trades under the ticker CTXR on NASDAQ.
Citius Pharmaceuticals, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Citius Pharmaceuticals, Inc. is 1506251. Its filings are on SEC EDGAR.
27,452,570 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Citius Pharmaceuticals, Inc. under United States.
Our directory classifies Citius Pharmaceuticals, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Citius Pharmaceuticals, Inc. is US17322U3068.
aibio.space lists Citius Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
$9.2 million in the fiscal year ended Sep 30, 2025, per its annual report.
$17.0 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Citius Pharmaceuticals, dated Oct 23, 2026: "Citius Oncology gets Nasdaq extension to April 19, 2027 on bid price". Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million. Source.
From our story of Apr 24, 2026: The prospectus supplement also reports substantial doubt about its ability to continue as a going concern. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio